Gut microbiome and metabolic response in non-alcoholic fatty liver disease
| Autor: | Kaviyarasi Renu, Sabariswaran Kandasamy, C.R. Sundara Rajan, Shweta Priyadarshini Dash, Raja Ganesan, Asmita Madatali Abuwani, Abilash Valsala Gopalakrishnan, Balachandar Vellingiri |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Hepatitis
Proteomics Cirrhosis business.industry Biochemistry (medical) Clinical Biochemistry Fatty liver General Medicine medicine.disease Bioinformatics Biochemistry Gastrointestinal Microbiome Metabolomics Non-alcoholic Fatty Liver Disease medicine Metabolome Humans Microbiome Obesity Metabolic syndrome Liver cancer business |
| Zdroj: | Clinica chimica acta; international journal of clinical chemistry. 523 |
| ISSN: | 1873-3492 |
| Popis: | Fatty liver disease (FLD) is one of the largest burdens to human health worldwide and is associated with gut microbiome and metabolite stability. Engineered liver tissues have shown promise in restoring liver functions in non-alcoholic FLD (NAFLD), hepatitis and cirrhosis. Fatty liver, largely noted in obesity and hepatic cancer, is highly fatal and has led to a global increase in death rates. It is associated with complex metabolic reprogramming too. A standard approach to therapy in the newly diagnosed setting includes surgery or identification of biomarkers/ metabolites for therapeutic purposes, which ultimately focus on improvement of liver health in patients. As such there are no standard procedures for patient care, but depending on the severity, systemic therapy with either genomic, proteomic or metabolomic profiling form potential options. Better comparisons and study of underlying mechanisms in gut microbiome-based metabolic functions in obesity are urgently required. Today, an emerging field, focusing on metabolomic approaches and metabolic phenotyping, involved in high-throughput identification of metabolome in obesity and gut disorders, is involved in biomarker and metabolite identification. There are supporting technologies and approaches in NAFLD that throw light on the metabolites and gut microbiome, and also on the understanding of the risk factors of obesity along with liver cancer metabolic reaction networks. We discuss the current state of NAFLD metabolites, gut micro-environmental changes, and the further challenges in digital metabolomics profiling. Innovative clinical trial designs, with biomarker-enrichment strategies that are required to improve the outcome of NAFLD in patients are also discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect